This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
WILDING, GEORGE
| Item Type | Name |
|
Concept
|
Vitamin D
|
|
Concept
|
Ergocalciferols
|
|
Concept
|
Vitamin E
|
|
Academic Article
|
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin e 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer
|
|
Academic Article
|
Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.
|
|
Academic Article
|
Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells.
|
|
Academic Article
|
Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer.
|
|
Academic Article
|
Growth inhibition and differentiation in human prostate carcinoma cells induced by the vitamin D analog 1alpha,24-dihydroxyvitamin D2.
|
|
Academic Article
|
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
|
|
Academic Article
|
Pretreatment with anti-oxidants sensitizes oxidatively stressed human cancer cells to growth inhibitory effect of suberoylanilide hydroxamic acid (SAHA).
|
|
Academic Article
|
Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1a-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin.
|
|
Academic Article
|
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1a,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.
|
|
Academic Article
|
A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer.
|